ライフサイエンスコーパス: corneal graft

1 les in these mice induced acute rejection of corneal grafts.

2 nition have the ability to reject allogeneic corneal grafts.

3 ents for orthotopic syngeneic and allogeneic corneal grafts.

4 ulceration, or corneal neovascularization on corneal grafts.

5 Of the DMEKs, 196 (55%) used preloaded corneal grafts.

6 estigated whether CHIKV is transmittable via corneal grafts.

7 onors of combined MHC and minor H-mismatched corneal grafts.

8 ecessary for the rejection of MHC-mismatched corneal grafts.

9 o play in determining the fate of orthotopic corneal grafts.

10 gene expression in syngeneic and allogeneic corneal grafts.

11 ossed corneal surface wounds, and orthotopic corneal grafting.

12 RNA-sequencing was performed on corneal grafts 2 weeks post-transplantation.

13 (11.8% vs 0%, P = .03), previous history of corneal graft (20.6% vs 0%, P = .0012), and prior topica

14 e led to the improved success rate for clear corneal grafts after penetrating keratoplasty.

15 e hydrops, and have improved the survival of corneal grafts after transplantation for resolved hydrop

16 likely to perforate or require an emergency corneal graft, after adjusting for baseline ulcer depth

17 eal grafts had swift rejection of subsequent corneal grafts and exhibited strong donor-specific DTH.

18 ity, intraocular pressure (IOP), survival of corneal grafts, and success of glaucoma surgery (defined

19 For full-thickness corneal grafts, antifungal supplementation was less cost

20 In addition, minor Ag-mismatched corneal grafts are more readily rejected than their MHC-

21 presenting passenger Langerhans cells in the corneal graft; (b) expression of Fas ligand on the epith

22 Highly inflamed and neovascularized corneal graft beds are known as high-risk (HR) environme

23 l keratoplasty procedure or cut from a whole corneal graft button unsuitable for keratoplasty.

24 o receive a B-KPro using a frozen or a fresh corneal graft carrier on the basis of tissue availabilit

25 erm clinical outcomes of fresh versus frozen corneal graft carriers for the Boston Keratoprosthesis t

26 In the latter type of corneal grafts, CD95L expression on the endothelium play

27 Laser IVCM was performed in the corneal grafts centrally.

28 significantly increased opacity of C57BL/6J corneal grafts, compared with the relatively clear graft

29 low-risk eyes of mice, most of the composite corneal grafts composed of syngeneic epithelium layered

30 Recipients of composite corneal grafts containing syngeneic epithelial layers ac

31 at at least three additional features of the corneal graft contribute to its immune privileged status

32 elial keratoplasty cases that used preloaded corneal grafts cost $460.19 less ($316.23-$604.14; P < 0

33 mph nodes (LNs), we tracked the migration of corneal graft-derived transgenic green fluorescent prote

34 is promotes systemic Th2 immune responses to corneal graft donor alloantigens; 2) corneal allografts

35 iver exogenous gene(s) to the endothelium of corneal grafts during hypothermic organ preservation.

36 ons included retinal detachment (2), chronic corneal graft failure (2), phthisis (1) and band keratop

37 The most common indication for surgery was corneal graft failure (n = 50; 44%) followed by chemical

38 PKP has significant implications leading to corneal graft failure and irreversible vision loss from

39 Corneal graft failure arising after trabeculectomy was s

40 Corneal graft failure was defined as persistent corneal

41 favorable outcomes of KPro surgery for donor corneal graft failure with a greater likelihood of maint

42 electronic medical records and evaluated for corneal graft failure, defined as irreversible and visua

43 diated rejection is the most common cause of corneal graft failure.

44 interfering with chemokine action to prevent corneal graft failure.

45 has been identified as a predictor of future corneal graft failure.

46 of MHC-matched, multiple minor H-mismatched corneal grafts fell from 80% in untreated controls to 36

47 t rejection is frequent in the 2 years after corneal graft for KC.

48 Most penetrating corneal grafts for Fuchs dystrophy or PACE remain clear

49 Twelve corneal grafts from 12 patients (7 men and 5 women) aged

50 allografts were no different than those for corneal grafts from Fas-bearing C57BL/6 donors.

51 - and wild-type C57BL/6 (ICAM-1+/+) received corneal grafts from the following strains of mice: BALB/

52 nstituted with CLNs from hosts with rejected corneal grafts had swift rejection of subsequent corneal

53 Partial thickness corneal grafts have favorable long-term outcome as a pat

54 rneal graft, prevented rejection of a second corneal graft in the same strain combination.

55 s results in the permanent acceptance of NZB corneal grafts in 60% and 90% of the CB6F1 hosts, respec

56 orneal grafts showed rejection of subsequent corneal grafts in a manner that was indistinguishable fr

57 each of the three cell layers of orthotopic corneal grafts in mice.

58 transplantation of fully allogeneic skin and corneal grafts in mice.

59 rence in survival of fully-mismatched BALB/c corneal grafts in p55-/- (n=12; P=0.76) or in double-kno

60 rvival of minor alloantigen-disparate BALB.b corneal grafts in p75-/- (n=13; P=0.95) or in combined p

61 There were more perforations and emergency corneal grafts in the chlorhexidine arm (24/175, 13.7%)

62 In corneal grafts, in vivo relative thickening of the En/DM

63 ophthalmologic examination before and after corneal graft, including VA, assessed by the preferentia

64 The major complication noted was corneal graft infection in 8 eyes (28.5%).

65 Corneal grafting is by far the most common form of trans

66 To examine the widely accepted dogmas that corneal grafts lack passenger leukocytes or cells capabl

67 The partial thickness corneal grafts maintained clarity throughout follow-up w

68 ute can alleviate this reliance on cadaveric corneal graft material.

69 Corneal graft melting occurred in 3 (6.7%) eyes.

70 on were activated directly in both skin- and corneal-grafted mice, only CD8+ T cells from skin-transp

71 unized hosts rejected their fully allogeneic corneal grafts (MST = 43 days) compared with 100% reject

72 Rejection of TNFRII KO corneal grafts occurred even though suppressor cells dev

73 In addition to multiple failed corneal grafts, other ocular conditions for which the Bo

74 The total number of corneal grafts performed annually is increasing steadily

75 n to determine the fate of similar composite corneal grafts placed in high-risk mouse eyes.

76 These studies have been extended to include corneal grafts placed in neovascularized high-risk eyes

77 One hundred thirty-nine eyes (96 corneal grafts post penetrating keratoplasty or Descemet

78 ce who had already been primed by a previous corneal graft, prevented rejection of a second corneal g

79 of mice, removal of the DLN before a second corneal graft procedure was performed.

80 ng sixty eyes (60 patients) at high risk for corneal graft rejection (GR) because of previous immunol

81 les, saline, or DSP in solution demonstrated corneal graft rejection accompanied by severe corneal ed

82 ickness (En/DMT) are of predictive value for corneal graft rejection after high-risk corneal transpla

83 ncompatibility (including H-Y mismatches) on corneal graft rejection and failure was evaluated using

84 that CD8(+) CTLs are essential in promoting corneal graft rejection and instead further implicates d

85 tion of allospecific effector macrophages in corneal graft rejection and the role of CD4(+) T cells a

86 y selected controls who did not experience a corneal graft rejection at their matched cases' index da

87 icroscopy (IVCM) can aid in the diagnosis of corneal graft rejection by detecting cellular corneal ch

88 Assessment of patients with corneal graft rejection by IVCM may serve as an adjuncti

89 Patients with corneal graft rejection demonstrate a significant increa

90 tained release of corticosteroids to prevent corneal graft rejection following subconjunctival inject

91 unct to prevent graft neovascularization and corneal graft rejection in high-risk corneal transplants

92 Corneal graft rejection in IFN-gamma-deficient hosts was

93 ed further the role of the DLN and spleen in corneal graft rejection in mice.

94 Thus, MHC matching may reduce the risk of corneal graft rejection in patients with atopic keratoco

95 study is to develop a pre-clinical model of corneal graft rejection in the semi-inbred NIH minipig a

96 Thus, allergy-induced exacerbation of corneal graft rejection is due to the production of IL-4

97 eye, so the required frequency of dosing for corneal graft rejection management can be as high as onc

98 rts have documented uveitis flares and acute corneal graft rejection occurring within the first 3 wee

99 The B6 corneal graft rejection rate in BALB/c vs Jalpha281 knoc

100 HC matching dramatically reduces the risk of corneal graft rejection when IFN-gamma is depressed or a

101 ., the SM node, is the major DLN involved in corneal graft rejection whereas its nearest neighbor, th

102 3D En/DMT maps can diagnose active corneal graft rejection with excellent accuracy, sensiti

103 approach for safely preventing and treating corneal graft rejection with the potential for improved

104 with penetrating keratoplasty (15 eyes with corneal graft rejection, 23 eyes without rejection) and

105 uggested a role for Fas-induced apoptosis in corneal graft rejection, additional experiments indicate

106 Alloantibody, although not necessary for corneal graft rejection, can produce extensive injury to

107 se of corticosteroids may reduce the rate of corneal graft rejection, perhaps especially in the days

108 correlated to clinical signs and symptoms of corneal graft rejection.

109 e presence of clinical signs and symptoms of corneal graft rejection.

110 s into the cornea with the aim of preventing corneal graft rejection.

111 or is administered after surgery, to prevent corneal graft rejection.

112 othesis that CTLs are essential in promoting corneal graft rejection.

113 associated with CD8(+) T cells, in promoting corneal graft rejection.

114 tive tool in the diagnosis and management of corneal graft rejection.

115 e as effective as viable cells in preventing corneal graft rejection.

116 is the mainstay for preventing and treating corneal graft rejection.

117 omplex (En/DM) characteristics in diagnosing corneal graft rejection.

118 esis is associated with an increased rate of corneal graft rejection.

119 r postoperative management and prevention of corneal graft rejection.

120 ng IL-17A at this time significantly reduced corneal graft rejection.

121 ive and prognostic role of 3D En/DMT maps in corneal graft rejection.

122 s demonstrated to be markedly upregulated in corneal graft rejection.

123 mmune responses and reduces the incidence of corneal graft rejection.

124 contribution of donor-specific antibodies to corneal graft rejection.

125 The corneal graft remained clear in nine eyes (40.9%) at a m

126 nstituted with CLNs from hosts with accepted corneal grafts showed rejection of subsequent corneal gr

127 At 4 degrees C (corneal graft storage temperature), significant amounts

128 ic epithelium protects orthotopic allogeneic corneal grafts (stroma plus endothelium) placed in high-

129 ed elevated intraocular pressure (IOP) after corneal graft surgery were included.

130 mplications related to trabeculectomy and/or corneal graft surgery.

131 BAT glare responses identified that the hazy corneal graft surrounding the KPro is the main source of

132 i-CD80/86 antibodies significantly prolonged corneal graft survival and decreased IFN-gamma(+)-produc

133 cells is an effective strategy for enhancing corneal graft survival and preventing graft rejection in

134 uded change in best corrected visual acuity, corneal graft survival and retinal reattachment at final

135 specific immune tolerance leads to long-term corneal graft survival as evidenced by the higher surviv

136 i-CD80/86 antibodies significantly prolonged corneal graft survival by inhibiting T-cell proliferatio

137 tion can successfully restore sight in many, corneal graft survival decreases in eyes with chronic in

138 y signs of corneal rejection, leading to rat corneal graft survival for at least 6 months.

139 munization with donor corneal cells enhanced corneal graft survival in all three high-risk settings.

140 Results showed a significant increase in corneal graft survival in alpha-MSH-treated recipients c

141 Corneal graft survival in the 3 groups was calculated us

142 Because anti-CD1d mAb abrogated the corneal graft survival in the wild-type mice we conclude

143 c cells to induce oral tolerance and enhance corneal graft survival indicates that oral tolerance to

144 The overall corneal graft survival rates at 1, 5, 10, 15, and 20 yea

145 After combined surgery the rate of corneal graft survival was 52% (95% CI 0.41-0.62; I(2) 6

146 Corneal graft survival was calculated using Kaplan-Meier

147 B), was examined for its capacity to enhance corneal graft survival when given separately or conjugat

148 t with normal hamster serum had no effect on corneal graft survival, infusion of anti-gamma delta Ab

149 fixed cells retain their capacity to enhance corneal graft survival, it may be possible to store dono

150 Corneal graft survival, opacity, neovascularization, re-

151 osis, thereby compromising visual acuity and corneal graft survival.

152 GMs]), and the secondary outcome measure was corneal graft survival.

153 h a TKP are performed, approximately half of corneal grafts survive, anatomically successful retinal

154 the subconjunctival treatment group, 33% of corneal grafts survived (P < 0.01).

155 Epithelium-deprived corneal grafts survived in syngeneic recipients but were

156 Rag(-/-) mice, both allogeneic and syngeneic corneal grafts survived; endostatin remained high throug

157 as covered by a 300-micron partial thickness corneal graft taken either from a previous Descemet stri

158 Surprisingly, when corneal grafts that are undergoing this later phase of r

159 ing induction vs effector of alloimmunity in corneal grafts, the most common form of tissue transplan

160 In addition, a global shortage of cadaveric corneal graft tissue critically limits accessibility to

161 ally quantified the considerable shortage of corneal graft tissue, with only 1 cornea available for 7

162 the long-term outcomes of partial thickness corneal grafts to cover the tube and prevent its exposur

163 fore and after surgery, mean follow-up time, corneal graft type, long-term complications, need for ad

164 Many corneal grafts undergo immune rejection, and current the

165 Corneal grafting was eventually performed in 7 of the 11

166 The overall average survival period for all corneal grafts was 42.9 months.

167 In vivo expression of GFP in syngeneic corneal grafts was demonstrated for up to 12 weeks.

168 gamma-producing CD4(+) T cell frequencies in corneal grafts were assessed with intraperitoneal inject

169 Corneal grafts were evaluated by ophthalmic slit-lamp bi

170 Corneal grafts were included from all deceased persons w

171 Moreover, all 31 of the TNFRII KO corneal grafts were rejected by naive BALB/c hosts.

172 CCR7(-/-) or wild-type (WT) allogeneic corneal grafts were transplanted onto the neovascularize

173 Corneal grafts were until recently considered entirely d

174 he posterior surface of accepted or rejected corneal grafts, whereas bone marrow-derived cells of rec

175 ss than 10% of the uncomplicated, first-time corneal grafts will undergo immune rejection even though

176 st deficiency in ICAM-1 promotes survival of corneal grafts with different degrees of allodisparity.